Loading...

SLNO SOLENO THERAPEUTICS INC Product Launches 8-K Filing

SLN

SLN

SOLENO THERAPEUTICS INC

(SLNO)

2025 8-K

Show Summary

Show Summary

Financial Statements

Accountant Change

Financial Results

Executive Compensation

FDA Review Extension

Financial Results

Financial Results Announcement

Sale Agreement with Jefferi...

Stock Grants to Employees

Lease Agreement

Annual Meeting of Stockholders

Financial Results Announcement

Public Offering of Common S...

FDA Breakthrough Therapy De...

Amendment to Inducement Equ...

Compensation Increase

Public Offering and Private...

Termination of Sales Agreement

Regulation FD Disclosure

Appointment of Director

Financial Results Announcement

Annual Meeting of Stockholders

Financial Results and Equit...

Completion of Enrollment in...

Financial Results Announcement

Amendment to Inducement Plan

Compensation Increases for ...

External Links:

On March 26, 2025, Soleno Therapeutics announced that its drug VYKATTM XR has been approved by the FDA for treating hyperphagia in patients with Prader-Willi syndrome.

AI Assistant

SOLENO THERAPEUTICS INC

2025

8 K

Find Answers

Ask about any part of the document to get insights, explanations, or key details.